Nivolumab + Ipilimumab
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Classic Kaposi Sarcoma
Conditions
Classic Kaposi Sarcoma
Trial Timeline
Apr 1, 2018 → Sep 1, 2022
NCT ID
NCT03219671About Nivolumab + Ipilimumab
Nivolumab + Ipilimumab is a phase 2 stage product being developed by Bristol Myers Squibb for Classic Kaposi Sarcoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03219671. Target conditions include Classic Kaposi Sarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02186249 | Pre-clinical | Completed |
| NCT07024862 | Pre-clinical | Active |
| NCT06487156 | Pre-clinical | Active |
| NCT05219435 | Phase 2 | Active |
| NCT05302921 | Phase 2 | Completed |
| NCT05088889 | Phase 1 | UNKNOWN |
| NCT04966676 | Phase 2 | Terminated |
| NCT05215470 | Phase 2 | Active |
| NCT04465643 | Phase 1 | Completed |
| NCT04938232 | Phase 2 | Active |
| NCT04495010 | Phase 2 | Withdrawn |
| NCT04513522 | Approved | Completed |
| NCT04434560 | Phase 2 | Terminated |
| NCT04575922 | Phase 2 | UNKNOWN |
| NCT04340193 | Phase 3 | Completed |
| NCT04088500 | Phase 2 | Terminated |
| NCT04361162 | Phase 2 | Active |
| NCT03873402 | Phase 3 | Active |
| NCT03461952 | Phase 2 | Terminated |
| NCT03789110 | Phase 2 | Active |
Competing Products
15 competing products in Classic Kaposi Sarcoma